1372PSurvival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018. (23rd October 2018) - Takiguchi, Y; Yamada, K; Tanaka, H; Kubota, K; Kishi, K; Shimokawa, T; Saito, H; Hosomi, Y; Kato, T; Nogami, N; Igawa, S; Kasai, T; et al.